Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,597 across all filing types
Latest filing 2014-07-14 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
2011年第三次临时股东大会决议等
Regulatory Filings Classification · 95% confidence The document text consists almost entirely of repeated placeholders indicating omitted pictures, with no substantive textual content or financial data present. There are no references to any specific report type, regulatory body, fiscal period, or financial figures. The document length is 9086 characters, which is relatively short and contains no actual report content, only placeholders. According to the 'Menu vs Meal' rule, this is not the report itself but likely an announcement or a placeholder document. Since it does not fit any specific category and lacks meaningful content, the best classification is Regulatory Filings (RNS), which serves as a fallback category for miscellaneous filings that do not fit other categories.
2014-07-14 Chinese
公司章程（草案）
Regulatory Filings Classification · 95% confidence The document text consists almost entirely of repeated placeholders indicating omitted pictures, with no substantive textual content or financial data present. There are no references to any report titles, fiscal periods, regulatory bodies, or specific financial information. The document length is 15,000 characters, but the content is essentially non-informative and does not contain any report or announcement text. Given the absence of any meaningful content, this document does not represent a full report or detailed announcement. It is best classified as a Regulatory Filing (RNS), which serves as a fallback category for filings that do not fit other specific categories or lack substantive content.
2014-07-14 Chinese
首次公开发行股票招股意向书摘要
Capital/Financing Update Classification · 95% confidence The document is titled as a "首次公开发行股票招股意向书摘要" which translates to "Summary of Prospectus for Initial Public Offering (IPO)". It contains detailed information about the company's IPO plan, including share issuance, shareholder commitments, risk factors, financial data for recent years, and underwriting details. The document is not a full annual or quarterly report, nor is it an earnings release or a regulatory announcement. It is a prospectus summary related to the company's initial public offering, which is a capital raising activity. Therefore, the document fits best under the category of Capital/Financing Update (CAP), as it provides detailed information about the company's stock issuance and related commitments for the IPO.
2014-07-14 Chinese
首次公开发行股票初步询价及推介公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial public offering (IPO) of Guangdong Taicheng Pharmaceutical Co., Ltd. It includes information about the preliminary inquiry and promotion of the IPO, the underwriting process, investor participation conditions, pricing principles, allocation mechanisms, and important dates related to the IPO process. The document references regulatory frameworks and specific dates in 2014 related to the IPO. It is not a financial report, earnings release, or management discussion but rather a formal announcement about the IPO process and related investor instructions. This fits the category of Capital/Financing Update (CAP), as it provides updates on the company's fundraising activities and capital issuance.
2014-07-14 Chinese
审计报告
Regulatory Filings Classification · 90% confidence The document text consists almost entirely of repeated lines indicating omitted pictures, with no substantive textual content or financial data present. There are no references to any specific report type, regulatory body, fiscal period, or financial figures. The document length is 15,000 characters, but the content is essentially placeholders for images, suggesting this is not the actual report but possibly a placeholder or an announcement. Given the absence of any detailed financial or management information, and no indication that this is a call transcript, audit report, or any other specific filing, the best fit is the fallback category Regulatory Filings (RNS).
2014-07-14 Chinese
国浩律师（深圳）事务所关于公司首次公开发行A股并上市的补充法律意见书（七）
Regulatory Filings Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding the initial public offering (IPO) and listing of Guangdong Taicheng Pharmaceutical Co., Ltd. It discusses the legal compliance, shareholder meetings, issuance plans, financial audits, corporate governance, and other regulatory requirements related to the company's IPO process. The document references audit reports, legal opinions, shareholder resolutions, and compliance with securities laws and regulations. It is not a financial report like an annual or interim report, nor is it a simple announcement or certification. Instead, it is a comprehensive legal opinion related to the IPO process, which fits the category of Regulatory Filings (RNS) as it is a regulatory compliance document that does not fit into other specific categories such as Audit Report or Annual Report. The document length is substantial and contains substantive content, not just an announcement or certification. Therefore, the best classification is Regulatory Filings (RNS).
2014-07-14 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.